Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.

Recs

0
Player Avatar adunlap13 (< 20) Submitted: 2/25/2013 1:46:37 PM : Outperform Start Price: $1.99 LXRX Score: -46.58

Big diabetes market for there main drug LX4211. It's the only drug that inhibits SLGT1 and SLGT2 which can treat both type 1 diabetes and type 2. No one has taken notice of this stock yet. They are also going to be partnering in the next few months with a large biopharma company to get LX4211 rolling.

Featured Broker Partners


Advertisement